German vaccine maker BioNTech said on Tuesday that it plans to invest up to 1 billion pounds ($1.33 billion) over the next ...

The agreement between BioNTech’s subsidiary BioNTech UK and the UK government is focused on accelerating clinical trials for ...

German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an ...

U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

The FDA had given Pfizer and Moderna until May 17 to propose changes to the labels of their COVID-19 vaccines or challenge ...

BioNTech will invest up to £1bn in UK life sciences over 10 years, launching new AI and R&D centres in London and Cambridge.

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

Hundreds of highly skilled jobs will be created, and new research centres will be set up aimed at making new advances in ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

German biopharma company BioNTech has said it will commit up to £1 billion ($1.34 billion) in investment in the UK over the ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.